Key facts
- Cytokinetics has launched its heart drug, Myqorzo, in Germany.
- This is the drug's first launch in a European market.
The launch of Myqorzo in Germany represents a key step for Cytokinetics in expanding the drug's market presence in Europe. Germany is a major pharmaceutical market, and its adoption of the drug could pave the way for further launches across the continent.